tbuckley/cabot-search huggingface dataset:
Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0
Authors: Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning
Journal: Clinical and Molecular Hepatology (2025)

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.
Performance of large language models in rheumatology board-like questions: accuracy, quality, and safety
Authors: Jaime Flores-Gouyonnet, María C Cuéllar-Gutiérrez, Gabriel Figueroa-Parra, Bradly Kimbrough, Elena K Joerns, Erika Navarro-Mendoza, Cynthia S Crowson, Ryan J Lennon, Mario Bautista-Vargas, Mariana González-Treviño, Alain Sanchez-Rodriguez, Alí Duarte-García
Journal: The Lancet Rheumatology (2025)
Tuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary
Authors: Morgana D'Ottavi, Peter Godfrey-Faussett, Corinne S Merle, Mircea T Sofonea, Didier Laureillard, Peter Vickerman, Jean-Pierre Molès, Frederick L Altice, Philippe Van de Perre, Jack Stone, Nicolas Nagot
Journal: The Lancet Global Health (2025)
Unique considerations in the assessment and management of traumatic brain injury in older adults
Authors: Bart Depreitere, Clemens Becker, Mario Ganau, Raquel C Gardner, Alexander Younsi, Alfonso Lagares, Niklas Marklund, Victoria Metaxa, Susanne Muehlschlegel, Virginia F J Newcombe, Lara Prisco, Mathieu van der Jagt, Joukje van der Naalt
Journal: The Lancet Neurology (2025)
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis
Authors: Anthony J Garcia-Prats, Maria Garcia-Cremades, Vivian Cox, Tamara Kredo, Rory Dunbar, H Simon Schaaf, James A Seddon, Jennifer Furin, Jay Achar, Kendra Radke, Tina Sachs, Amanzhan Abubakirov, Saman Ahmed, Onno W Akkerman, Nadia Abdulkareem Al Ani, Farhana Amanullah, Nafees Ahmad, Laura F Anderson, Meseret Asfaw, Funeka Bango, Torsten Bauer, Mercedes Becerra, Martin Boeree, Folke Brinkmann, Rosemary Brown, James Brust, Jonathon R Campbell, Anna Cristina Carvalho, Isabel Carvalho, J Peter Cegielski, Rosella Centis, Edward D Chan, Sandeep Chauhan, Silvia S Chiang, Pei-Chun Chan, Lia D'Ambrosio, Margareth Dalcolmo, Narine Daneilyan, Gerard de Vries, Heather R Draper, Lee Fairlie, Joshua R Francis, Molly Franke, Medea Gegia, Camilo Gomez Restrepo, Annette Guenther, Tatyana Gureva, Brit Haecker, Elizabeth Harausz, Catherine Hewison, Robert M Hicks, Helena Huerga, Jennifer Hughes, Petros Isaakidis, Syed M Kadri, Mazhar Ali Khan, Tinatin Kotrikadze, Liga Kuksa, Nathalie Lachenal, Christoph Lange, Leonid Lecca, Elisa Lopez-Varela, Sheila Lucena, Andrei Mariandyshev, Sanjay Mattoo, Ana Mendez-Echevarria, Giovanni Battista Migliori, Carole Mitnick, Erika Mohr-Holland, Winston Mulanda, Totugul Murzabakova, Bakyt Myrzalieve, Norbert Ndjeka, Stefan Niemann, Iveta Ozere, Nesri Padayatchi, Malik Parmar, Nargiza Parpieva, Mohammad Manzur-Ul-Alam, Natasha Rybak, Kuldeep Singh Sachdeva, Kelly Salmon, Begoña Santiago-Garcia, Dagmar Schaub, Ira Shah, Sarita Shah, Vaibhav Shah, Sangeeta Sharma, Tae Shun Shim, Sonya Shin, Animesh Sinha, Alena Skrahina, Hardik Solanki, Belen P Solans, Antoni Soriano-Arandes, Atyrkul Toktogonova, Tjip van der Werf, Gustavo E Velásquez, Bhanu Williams, Jae-Joon Yim, Rada Savic, Anneke Hesseling
Journal: The Lancet Child & Adolescent Health (2025)
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
Authors: Kristy K L Coleman, Scott Berry, Jeffrey Cummings, Ging-Yuek R Hsiung, Robert Laforce, Edward Huey, Simon Ducharme, Maria Carmela Tartaglia, Mario F Mendez, Chiadi Onyike, Kimiko Domoto-Reilly, Mario Masellis, Nathan Herrmann, Anton Porsteinsson, Michelle A Detry, Chloe Stewart, Anna L Bosse, Anna McGlothlin, Bryan Dias, Sachin Pandey, Michael Mayich, Stephen H Pasternak, Ramiro Ruiz Garcia, Miguel Restrepo-Martinez, Howard Feldman, Adam L Boxer, Elizabeth C Finger
Journal: The Lancet Neurology (2025)
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Authors: Ali A Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França, Jorge Gustavo José, Gerd Meyer Zu Hörste, Elżbieta Klimiec-Moskal, Michael T Pulley, Darío Tavolini, Petranka Krumova, Siân Lennon-Chrimes, Jillian Smith, Gian-Andrea Thanei, Kathleen Blondeau, Ivana Vodopivec, Gil I Wolfe, Hiroyuki Murai
Journal: The Lancet Neurology (2025)
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
Authors: Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Yasushi Suzuki, Eriene Youssef, Panna Sanga, Keith Karcher, Yaowei Zhu, John J Sheehan, Hong Sun
Journal: The Lancet Neurology (2025)
Admission to acute medical wards for mental health concerns among children and young people in England from 2012 to 2022: a cohort study
Authors: Joseph L Ward, Adriana Vázquez-Vázquez, Kirsty Phillips, Kate Settle, Hanifa Pilvar, Francesca Cornaglia, Faith Gibson, Dasha Nicholls, Damian Roland, Gabrielle Mathews, Helen Roberts, Russell M Viner, Lee D Hudson
Journal: The Lancet Child & Adolescent Health (2025)
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial
Authors: Ashkan Shoamanesh, Thalia S Field, Shelagh B Coutts, Mukul Sharma, David Gladstone, Robert G Hart, Giuseppe Boriani, David J Wright, Christian Sticherling, David H Birnie, Michael R Gold, Julia W Erath, Valentina Kutyifa, Rajibul Mian, Alexander P Benz, Christopher B Granger, William F McIntyre, Stuart J Connolly, Jens Cosedis Nielsen, Marco Alings, Lena Rivard, Renato D Lopes, Jeff S Healey
Journal: The Lancet Neurology (2025)
Disseminated mpox in an immunocompromised patient in DR Congo: a call for a shift from disease-focused to person-centred outbreak response
Authors: Patrick Musole Bugeme, Patrick Kazuba Bugale, Joël Zigashane Mashauri, André Ishara Kapalata, Levi Bugwaja, Trust Faraja Mukika, Salomon Mashupe Shangula, Philémon Hodari Sebiyoyo, Daniel Buuma Barungu, Willy Kasi, Justin Bengehya, Patrick D M C Katoto, Esto Bahizire, Louise C Ivers, Pauline Vetter, Andrew S Azman, Espoir Bwenge Malembaka
Journal: The Lancet Infectious Diseases (2025)
A Sustained H<sub>2</sub>/Fluorouracil‐Releasing Suppository for High‐efficacy and Low‐Toxicity Hydrogenochemotherapy of Colon Cancer
Authors: Danyang Chen, Zuan Wu, Chao Xia, Haiyan Yang, Wenjiang Ding, Qianjun He
Journal: Advanced Healthcare Materials (2025)

Abstract To attenuate the intestinal toxicity of chemotherapeutic drugs from rectal suppositories and enhance their chemotherapeutic outcome is greatly significant, but maintains a challenge. In this work, a new strategy of local synergistic hydrogenochemotherapy is proposed to attenuate side effects and enhance therapeutic efficacy based on the anti‐cancer selectivity and normal cells‐protecting effect of H 2 , and construct a novel anti‐cancer formulation of rectal suppository (5‐FU/CSN@FAG) by fatty acid glycerides (FAG) encapsulating 5‐fluorouracil (5‐FU, a first‐line drug for colorectal cancer treatment) and cerium silicide nanoparticles (CSN) with a sustained hydrolytic H 2 release behavior which is synchronous with 5‐FU release. The 3‐week treatment with the suppository once a day can not only completely eradicate colon tumors without tumor recurrence after suppository administration withdrawal, but also efficiently protect the intestinal tract from chemotherapeutic damage. Mechanistically, H 2 generated by CSN reduces the toxicity of 5‐FU to normal cells in the intestinal tract by scavenging over‐expressed reactive oxygen species and correcting energy metabolism, and also assists 5‐FU to promote the apoptosis of colon tumor cells by inhibiting their respiration through a CO signaling pathway. High biosafety and therapeutic validity endow the developed suppository with a high potential for clinical translation.
A Spiro‐Based NIR‐II Photosensitizer with Efficient ROS Generation and Thermal Conversion Performances for Imaging‐Guided Tumor Theranostics
Authors: Yu‐Kun Jin, Kang Xu, Bao‐Yi Ren, Jinjun Shao, Chang‐Jin Ou, Ling‐Hai Xie
Journal: Advanced Healthcare Materials (2025)

Abstract Organic photosensitizers (PSs) possessing NIR‐II emission and photodynamic/photothermal effect have received a great sense of attention for their cutting‐edge applications in imaging‐guided multimodal phototherapy. However, it is highly challenging to design efficient PSs with high luminescence and phototherapy performance simultaneously. In this study, a spiro‐functionalization strategy is proposed to alleviate aggregate‐caused quenching of PSs and promote photodynamic therapy, and the strategy is verified via a spiro[fluorine‐9,9ʹ‐xanthene]‐modified NIR‐II PS (named SFX‐IC) with an acceptor–donor–acceptor configuration. SFX‐IC‐based nanoparticles (NPs) display a high molar extinction coefficient of 7.05 × 10 4 m ‒1 cm −1 at 645 nm due to strong intramolecular charge‐transfer characteristics. As expected, the as‐prepared NPs show strong NIR‐II emission with a fluorescence quantum yield of 1.1%, thanks to the spiro‐configuration that suppressing excessively intermolecular π–π stacking. Furthermore, SFX‐IC NPs not only efficiently generate 1 O 2 and O ∙− 2 under 660 nm laser irradiation, but also possess good photothermal effect with photothermal conversion efficiency of 47.14%. Consequently, SFX‐IC NPs can be served as versatile phototheranostic agents for NIR‐II fluorescence/photoacoustic imaging‐guided phototherapy, manifesting that the spiro‐functionalized strategy is a powerful tool to construct efficient NIR‐II emitting PSs.
A Bioengineered Model of the Human Cornea for Preclinical Assessment of Human Ocular Exposure to Environmental Toxicants
Authors: Se‐jeong Kim, Ning Guo, Zong Yao Tan, Xing Gao, Pouria Fattahi, Haijiao Liu, Jeehan Chang, Mousa Younesi, Selice Jung, Yewhan Chung, Minkyung Song, Michelle Jung, Dan Dongeun Huh
Journal: Advanced Healthcare Materials (2025)

Abstract Here a bioengineered platform is introduced to investigate adverse effects of environmental materials on the human cornea. Using primary cells, this system is capable of reproducing the differentiated corneal epithelium and its underlying stroma in the human eye, which can then be treated with externally applied solid, liquid, or gaseous substances in a controlled manner and under physiologically relevant conditions. The proof‐of‐principle of how this system can be used to simulate human ocular exposure to different classes of environmental toxicants for direct visualization and quantitative analysis of their potential to induce acute corneal injury and inflammation is demonstrated. This model can also be further engineered to create an electromechanically actuated array of multiple human corneal tissues that can emulate spontaneous eye blinking. Using this advanced system, it is shown that blinking‐like mechanical motions may play a protective role against adverse effects of environmental toxicants. This work yields an immediately deployable in vitro technology for screening ocular toxicity of existing and emerging environmental materials of various types and may enable the development of more realistic, human‐relevant preclinical toxicology models complementary to traditional animal testing.
Correction: Clinical features, etiologies, and outcomes in adult patients with meningoencephalitis requiring intensive care (EURECA): an international prospective multicenter cohort study
Authors: Romain Sonneville, Etienne de Montmollin, Damien Contou, Ricard Ferrer, Mohan Gurjar, Kada Klouche, Benjamine Sarton, Sophie Demeret, Pierre Bailly, Daniel da Silva, Etienne Escudier, Loic Le Guennec, Russel Chabanne, Laurent Argaud, Omar Ben Hadj Salem, Martial Thyrault, Aurélien Frerou, Guillaume Louis, Gennaro De Pascale, Janneke Horn, Raimund Helbok, Guillaume Geri, Fabrice Bruneel, Ignacio Martin-Loeches, Fabio Silvio Taccone, Jan J. De Waele, Stéphane Ruckly, Quentin Staiquly, Giuseppe Citerio, Jean-François Timsit, Manuel Santafe, Roland Smonig, Damien Roux, Guillaume Voiriot, Bertrand Souweine, Keyvan Razazi, Thibault Duburcq, Mario Kofler, Patricia Boronat, Nadia Aissaoui, Danielle Reuter, Alain Cariou, Philippe Mateu, Barabara Balandin Moreno, Paula Vera, Estela Val Jordan, François Barbier, Mickael Landais, Jeremy Bourenne, Antoine Marchalot, Mathilde Perrin, Benjamin Sztrympf, Carole Schwebel, Shakti Bedanta Mishra, Patrick Chillet, Maelle Martin, Hugues Georges, Jean-Claude Lacherade, Romaric Larcher, Gregory Papin, David Schnell, Sulekha Saxena, Frank Chemouni, Juliette Audibert, Eric Mariotte, Shidasp Siami, Italo Calamai, Cédric Bruel, Alexandre Massri, Jesus Priego, Xavier Souloy, Pascal Beuret, Bikram Kumar Gupta, Thomas Ritzenthaler, Sami Hraiech, Aguila Radjou, M. K. Renuka
Journal: Intensive Care Medicine (2025)
Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease
Authors: Weifeng He, Lingfeng Yan, Dongxue Hu, Jianlei Hao, Yih‐Cherng Liou, Gaoxing Luo
Journal: MedComm (2025)

Abstract Neutrophils, the most abundant circulating leukocytes, have long been recognized as key players in innate immunity and inflammation. However, recent discoveries unveil their remarkable heterogeneity and plasticity, challenging the traditional view of neutrophils as a homogeneous population with a limited functional repertoire. Advances in single‐cell technologies and functional assays have revealed distinct neutrophil subsets with diverse phenotypes and functions and their ability to adapt to microenvironmental cues. This review provides a comprehensive overview of the multidimensional landscape of neutrophil heterogeneity, discussing the various axes along which diversity manifests, including maturation state, density, surface marker expression, and functional polarization. We highlight the molecular mechanisms underpinning neutrophil plasticity, focusing on the complex interplay of signaling pathways, transcriptional regulators, and epigenetic modifications that shape neutrophil responses. Furthermore, we explore the implications of neutrophil heterogeneity and plasticity in physiological processes and pathological conditions, including host defense, inflammation, tissue repair, and cancer. By integrating insights from cutting‐edge research, this review aims to provide a framework for understanding the multifaceted roles of neutrophils and their potential as therapeutic targets in a wide range of diseases.
Selective expression and significance of ACKR2 in lung aerocytes
Authors: Francesca Albano, Valeria Mollica Poeta, Lucia Zotti, Alessandra Castagna, Arianna Felicetta, Alessandro Mesaglio, Elisa Zaghen, Marina Sironi, Arianna Capucetti, Rachele Di Donato, Mattia Laffranchi, Matteo Massara, Roberta Carriero, Gianluigi Condorelli, Silvano Sozzani, Alberto Mantovani, Massimo Locati, Raffaella Bonecchi
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background ACKR2 is an atypical chemokine receptor that plays a significant role in regulating inflammation by binding to inflammatory CC chemokines and facilitating their degradation. Previous findings suggest that the genetic absence of ACKR2 leads to heightened tumor growth in inflammation-driven models. Conversely, mice lacking ACKR2 exhibit protection against lung metastasis in melanoma and breast cancer models. This study aims to explore the specific cell types expressing ACKR2 and their relative contributions to the protection against lung metastasis. Methods ACKR2 expression was studied by the generation of an inducible and conditional knockout (KO) mouse expressing two reporter genes, luciferase and TdTomato visible by In Vivo Imaging System, flow cytometry and immunofluorescence. Gene expression in lung endothelial cells (ECs) was investigated by RNA sequencing analysis. In vivo models of lung metastasis and inflammation were performed in wild-type (WT) and conditional KO mice by intravenous injection of melanoma and colon cancer cell lines; the induction of acute lung injury model was done by intranasal injection of lipopolysaccharide (LPS). Leukocytes infiltrating lung metastasis were studied by fluorescence-activated cell sorting (FACS) analysis. The serum chemokine levels were studied with a multiplex ELISA. Results The analysis of the reporter mouse revealed that ACKR2 is expressed by lymphatic endothelial cells (LECs) in most murine organs. However, uniquely in the lungs, ACKR2 expression is observed in blood endothelial cells (BECs), specifically in capillaries known as aerocytes specialized for regulating leukocyte trafficking. Selective deletion of Ackr2 from ECs (ACKR2 ΔCdh5 mice) but not from LECs (ACKR2 ΔProx1 mice) resulted in protection in models of melanoma and colorectal cancer lung metastasis. This protection was associated with an increased presence of activated T lymphocytes infiltrating the lungs compared with WT mice. Additionally, in a model of acute lung injury, mice with selective deletion from the endothelial compartment exhibited heightened extravasation of T lymphocytes compared with both ACKR2 KO and WT mice. Conclusions These results indicate that ACKR2 is selectively expressed by lung vascular capillaries (aerocytes) that are devoted to the regulation of leukocyte extravasation. Selective ACKR2 targeting in this compartment, by modulating chemokine availability, promotes T lymphocyte extravasation resulting in reduced lung metastases.
Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1
Authors: Zijun Zhang, Ziming Zhao, Changxing Qi, Xiaotian Zhang, Yang Xiao, Chengjuan Chen, Yu Zou, Xia Chen, Lianghu Gu, Jianzheng Huang, Kun Huang, Ming Xiang, Tiantai Zhang, Qingyi Tong, Yonghui Zhang
Journal: MedComm (2025)

Abstract Chronic kidney disease (CKD) is a disease that affects more than 850 million people. Acute kidney injury (AKI) is a common cause of CKD, and blocking the AKI–CKD transition shows promising therapeutic potential. Herein, we found that butyrolactone I (BLI), a natural product, exerts significant nephroprotective effects, including maintenance of kidney function, inhibition of inflammatory response, and prevention of fibrosis, in both folic acid‐ and ureteral obstruction‐induced AKI–CKD transition mouse models. Notably, BLI showed greater blood urea nitrogen reduction and anti‐inflammatory effects than telmisartan. Bioinformatics analysis and target confirmation assays suggested that BLI directly binds to JAK1, and kinase inhibition assay confirmed it is a potent JAK1inhibitor with an IC 50 of 0.376 µM. Experiments in JAK1‐knockdown mice also proved that BLI targets JAK1 to work. Furthermore, BLI demonstrated nephroprotective effects and safety comparable to ivarmacitinib, the well‐known JAK1 inhibitor. Mechanistically, BLI targets JAK1 and inhibits its phosphorylation and JAK‐STAT activation, subsequently regulating the downstream signaling pathways to inhibit reactive oxygen species production, inflammation, and ferroptosis, thereby preventing the occurrence of kidney fibrosis and blocking the AKI–CKD transition process. This study demonstrates for the first time that BLI is a JAK1 inhibitor and a promising candidate for delaying CKD progression, which warrants further investigation.
Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Authors: Resat Cinar, Abhishek Basu, Muhammad Arif, Joshua K. Park, Charles N Zawatsky, Ben Long G. Zuo, Mei Xing G. Zuo, Kevin J. O'Brien, Molly Behan, Wendy Introne, Malliga R. Iyer, William A Gahl, May Christine V. Malicdan, Bernadette R. Gochuico
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Targeting and reprogramming microglial phagocytosis of neutrophils by ginsenoside Rg1 nanovesicles promotes stroke recovery
Authors: Kaichao Hu, Junrui Ye, Pinglong Fan, Ruifang Zheng, Shasha Wang, Ye Peng, Yuan Ruan, Xu Yan, Zhao Zhang, Shifeng Chu, Naihong Chen
Journal: Bioactive Materials (2025)
Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI
Authors: Dominick J Angiolillo, Davide Capodanno
Journal: New England Journal of Medicine (2025)

This editorial describes the science behind a clinical trial reported by Ruff et al. in which a monoclonal antibody targeting factors XI and XIa was evaluated for its effects on bleeding events in patients with atrial fibrillation.
Multimodal Treatment in Locally Advanced Esophageal Adenocarcinoma — Two Interventions Better Than Three?
Authors: David P Kelsen
Journal: New England Journal of Medicine (2025)

Esophageal cancer is a highly lethal disease and the seventh leading cause of cancer-related death. In 2022, there were 511,000 new cases of esophageal cancer and 445,000 deaths from esophageal cancer worldwide.1 Esophageal cancer is made up of two distinct cancers arising in the same organ, with different causative factors and different genomic characteristics. Whereas esophageal squamous-cell carcinomas are more prevalent worldwide (85% of new cases of esophageal cancer), adenocarcinomas of the esophagus and esophagogastric junction (hereafter referred to as esophageal adenocarcinomas) are predominant in developed countries, comprising 75% of the new cases of esophageal cancer in the United States . . .
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History
Authors: Mary Eapen, Lynn M Malec, Myriam A Armant, Bryon D Johnson, Qizhen Shi, Huiqing Xu, Lily M Du, James H Jerkins, Lisa J Duffy, Frederic D Bushman, Carole Lee, Angelina Petrichenko, Peiman Hematti, Ruta Brazauskas, Shawn M Jobe, Parameswaran N Hari, David A Wilcox
Journal: New England Journal of Medicine (2025)

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen.